CINECA IRIS Institutional Research Information System

BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.511
EU - Europa 3.068
AS - Asia 1.419
AF - Africa 49
SA - Sud America 44
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.457
CN - Cina 621
DK - Danimarca 580
IT - Italia 506
SG - Singapore 461
IE - Irlanda 374
SE - Svezia 342
DE - Germania 264
FR - Francia 217
AT - Austria 169
UA - Ucraina 167
FI - Finlandia 139
GB - Regno Unito 115
IN - India 63
VN - Vietnam 63
KR - Corea 55
NL - Olanda 48
CA - Canada 38
BR - Brasile 35
HK - Hong Kong 34
ID - Indonesia 32
PL - Polonia 27
CZ - Repubblica Ceca 23
JP - Giappone 20
BE - Belgio 17
EG - Egitto 17
RU - Federazione Russa 17
TW - Taiwan 15
GR - Grecia 14
MX - Messico 14
RO - Romania 14
AU - Australia 13
PK - Pakistan 11
CH - Svizzera 10
ES - Italia 7
TH - Thailandia 7
UZ - Uzbekistan 6
EU - Europa 5
SD - Sudan 5
SN - Senegal 5
TR - Turchia 5
KE - Kenya 4
PS - Palestinian Territory 4
ZA - Sudafrica 4
CL - Cile 3
HU - Ungheria 3
IQ - Iraq 3
IR - Iran 3
JO - Giordania 3
LT - Lituania 3
NG - Nigeria 3
NO - Norvegia 3
PT - Portogallo 3
BG - Bulgaria 2
CO - Colombia 2
MU - Mauritius 2
MY - Malesia 2
NZ - Nuova Zelanda 2
TG - Togo 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CU - Cuba 1
EE - Estonia 1
GM - Gambi 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MA - Marocco 1
ME - Montenegro 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
PH - Filippine 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
UG - Uganda 1
UY - Uruguay 1
VE - Venezuela 1
Totale 10.111
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.203
Chandler 660
Beijing 381
Dublin 370
Santa Clara 324
Singapore 277
Fairfield 260
Houston 208
Woodbridge 195
Torino 178
Villeurbanne 168
Wilmington 161
Vienna 155
Dearborn 154
Nyköping 146
Ashburn 137
Medford 106
Princeton 104
Columbus 92
Cambridge 80
Fremont 80
Jacksonville 77
Seattle 73
Redwood City 72
Guangzhou 42
Milan 37
Pisa 37
Boardman 34
Boston 32
Jakarta 27
Dong Ket 26
Toronto 26
Hefei 22
Nanjing 22
Turin 22
Warsaw 22
Hong Kong 21
Nuremberg 21
New York 20
Shanghai 18
Brno 17
Munich 17
Helsinki 16
Verona 16
Brussels 15
Los Angeles 15
Jinan 14
Norwalk 14
Nürnberg 13
Falls Church 12
London 12
Mountain View 12
Taipei 11
San Diego 10
Des Moines 9
Hebei 9
Kharkiv 9
Rome 9
Cairo 8
Central District 8
Falkenstein 8
Hangzhou 8
Kunming 8
Leawood 8
Silver Spring 8
Hyderabad 7
Pune 7
Washington 7
Chengdu 6
Dallas 6
Pozzolo Formigaro 6
Zhengzhou 6
Zurich 6
Edinburgh 5
Fiano Romano 5
Mexico City 5
Nanchang 5
Ottawa 5
Phoenix 5
Tokyo 5
Weimar 5
Wuhan 5
Athens 4
Auburn Hills 4
Bari 4
Bengaluru 4
Chicago 4
Frankfurt am Main 4
Karachi 4
Mumbai 4
Nagold 4
Seoul 4
Windsor 4
Aachen 3
Amman 3
Amsterdam 3
Bangkok 3
Bloomington 3
Bucharest 3
Buffalo 3
Totale 6.537
Salva come PNG Salva come JPEG
Nome #
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 328
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 260
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 244
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 226
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 202
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 201
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 198
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 193
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 186
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 185
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 181
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 179
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 175
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 171
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 170
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 168
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 168
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 155
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 155
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 154
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 154
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 152
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 151
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 147
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 146
Influenza della somministrazione del metadone sulle concentrazioni plasmatiche di daclatasvir in una coorte di pazienti con epatite cronica da HCV e tossicodipendenza attiva. 144
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 141
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 136
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 136
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. 133
Ruolo della riduzione precoce di HBsAg per individuare i pazienti con infezione precoce da HBV, HBeAg-negativi e genotipo E ad alta probabilità di risposta sostenuta con 48 settimane di trattamento con PEG-INF ALFA-2A 127
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 123
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 120
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 119
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 117
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 112
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 108
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 107
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 105
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 104
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 103
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 99
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 98
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 98
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 97
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 97
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon]. 94
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 94
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 93
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 92
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 92
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 91
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 89
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 86
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 85
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 83
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 83
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 81
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 80
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 80
Role of intravenous immunoglobulin administration in Japanese encephalitis. 79
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 77
Co-infection with other respiratory pathogens in COVID-19 patients 77
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 75
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 73
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis 73
Combination therapy in chronic hepatitis B: what are the real benefits? 70
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 69
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 68
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 67
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 66
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 65
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 65
Klebsiella pneumoniae meningitis in a 38-year-old Chinese traveller with impaired glucose tolerance: A new emerging syndrome? 64
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir. 64
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 64
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 63
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection 63
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 63
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 62
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 61
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 61
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 60
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 58
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 58
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 54
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 54
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 52
Ceftobiprole perspective: Current and potential future indications 52
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 49
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 49
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 42
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 41
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 36
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 35
Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience 34
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 34
The Role of IL28B Genotype in HCV-RNA Baseline Levels 33
Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C 30
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers 28
Totale 10.584
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.182
article - articoli 0
book - libri 0
conference - conferenze 6.068
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.250
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020721 0 0 0 0 0 0 0 0 89 239 181 212
2020/20211.028 159 54 41 68 91 64 51 26 69 60 132 213
2021/20221.859 141 163 140 178 120 183 165 137 107 72 258 195
2022/20231.873 156 121 54 191 177 444 116 141 248 30 125 70
2023/2024574 84 100 27 30 39 81 17 30 6 29 41 90
2024/20251.208 18 93 73 164 492 105 36 111 116 0 0 0
Totale 10.624